MT027 cells suspension

DRUG3 trials

Sponsors

Suzhou Maximum Bio-tech Co., Ltd.

Conditions

Advanced Malignant Solid TumorBrain (Nervous System) CancersBrain TumorsBrain and Central Nervous System TumorsHigh-grade GliomaMalignant Pleural EffusionPleura CarcinomaPleural Malignant Mesothelioma

Phase 1

A Study of MT027 in Patients with Pleural Malignant Tumors

RecruitingNCT06726564

Suzhou Maximum Bio-tech Co., Ltd.Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma +3

Start: 2024-05-15End: 2029-02-28Target: 18Updated: 2024-12-10

Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma

Not yet recruitingNCT06737146

Suzhou Maximum Bio-tech Co., Ltd.High-grade Glioma

Start: 2025-01-01End: 2026-12-30Target: 12Updated: 2024-12-17

Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors

Not yet recruitingNCT06742593

Suzhou Maximum Bio-tech Co., Ltd.Brain and Central Nervous System Tumors, Brain (Nervous System) Cancers, Brain Tumors

Start: 2025-01-01End: 2026-12-30Target: 12Updated: 2024-12-19